Pharmacologic treatments for covid-19 patients
Pentoxifylline vs Standard care/Placebo
This comparison will not be updated. Last search date 28 Feb, 2022.
Hospitalized patients
Forest plots
(last update: 2021-11-05)
To access all information :
- click here for Hospitalized patients
You can print it as a pdf. You can also click on each forest plot with your right mouse button and download.
Permanent URL for this comparison: https://covid-nma.com/living_data/index.php?comparison=170
Back to your research
| Trial | Funding | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
|---|---|---|---|---|---|---|---|---|
| Treatment 1 | Treatment 2 | |||||||
| IRCT20190804044429N4 Azizi H, nt Immunopharmacol, 2021 Full text Commentary |
Public/non profit |
Pentoxifylline |
Placebo |
RCT | Patients with suspected or confirmed COVID-19 (mild-moderate-severe) admitted to a single centre in Iran | N=102 |
Some concerns Details |
|
| N/A Maldonado V, INT IMMUNOPHARMACOL, 2020 Full text Commentary |
No specific funding |
Pentoxifylline |
Standard care |
RCT | Patients with confirmed COVID-19 (moderate-severe) admitted to a single center in Mexico | N=54 | N/A | |